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Canada
Early graft failure is a complex and challenging clinical condition faced by vascular surgeons performing infrainguinal
bypass surgery. This case describes a patient with undiagnosed thrombocytosis undergoing urgent open revascularization
for critical limb ischemia. The operative case was complicated by recurrent on-table acute thrombosis that was successfully
managed with intravenous glycoprotein IIb/IIIa antagonism with eptiﬁbatide. This is a novel case of its use for on-table
salvage of an infrainguinal bypass graft. This case report outlines this challenging clinical problem and a novel use for
glycoprotein IIb/IIIa antagonists. (J Vasc Surg Cases 2015;1:246-8.)CASE REPORT
A 91-year-old woman was referred emergently to our ser-
vice from hematology with a short history of rest pain in her
left foot, with dry gangrene affecting the ﬁrst three toes. Con-
sent was obtained from the patient’s power of attorney to pub-
lish this case report. She had a background history of
osteoarthritis, hypertension, and hypercholesterolemia, and she
had an initial consultation with a hematologist for an undiag-
nosed elevated platelet count of 891  109/L. Her hemoglobin
level was 13 g/dL, and the white blood cell count was 20.7 
109/L despite absence of infection. Her medications included
ramipril, metoprolol, and aspirin. She was noted to have a
palpable femoral pulse but no palpable pulses distal to this,
and the left foot was cold, with dry gangrene affecting the distal
portions of the ﬁrst three toes. Noninvasive vascular studies
revealed an occluded superﬁcial femoral artery with no obtain-
able pressure at the ankle. Percutaneous diagnostic angiography
demonstrated occluded distal superﬁcial femoral, popliteal, and
tibial arteries with reconstitution of the posterior tibial artery,
which constituted the only patent named vessel crossing the
ankle (Fig). Duplex sonography conﬁrmed an excellent left leg
long saphenous venous conduit, and echocardiography revealed
an ejection fraction of >60%. Given her critical limb ischemia, in
consultation with hematology, priority was given to addressing
her peripheral vascular disease. Therefore, despite her advanced
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://dx.doi.org/10.1016/j.jvsc.2015.08.004femorotibial bypass from her superﬁcial femoral artery to her
posterior tibial using a long saphenous venous conduit was per-
formed. She was anticoagulated intraoperatively with intrave-
nous heparin to maintain an activated clotting time of
>300 seconds. The inﬂow and outﬂow vessels were of excellent
quality, and an excellent graft pulse and target vessel pulse/
Doppler signal were achieved. Immediately before skin closure,
the graft pulse was noted to be absent. A graft thromboembolec-
tomy was performed through a conduit side branch distally. We
retrieved a signiﬁcant amount of white thrombus, and graft ﬂow
was restored. A bolus of clopidogrel was administered through
nasogastric tube; however, before closing of the wounds, the
graft occluded a second time. Another thromboembolectomy
again restored graft ﬂow after retrieval of a signiﬁcant amount
of white thrombus. The clinical picture was consistent with
recurrent on-table graft occlusion secondary to platelet-rich
white thrombus in the setting of an underlying thrombocytosis.
Heparin-induced thrombocytopenia was considered unlikely as
she had no prior exposure or immediate drop in platelet count.
We administered the glycoprotein IIb/IIIa antagonist eptiﬁba-
tide to suppress platelet function. A bolus of 60 mg/kg was
administered, followed by a continuous intravenous infusion
rate of 0.7 mg/kg/min while the patient was still on the oper-
ating table. To measure response, rotational thromboelastogra-
phy was used (ROTEM; TEM Systems, Durham, NC) to
assess platelet function. Thromboelastography conﬁrmed 82%
platelet inhibition. No further on-table thrombosis of the graft
occurred, and the surgery was completed successfully. Postoper-
atively, the patient was continued on an eptiﬁbatide infusion,
and hydroxyurea was commenced for a presumed diagnosis of
myeloproliferative disorder; her platelet function was monitored
by the platelet aggregation assay to ensure that despite her
elevated platelet count, her functioning platelet count was sup-
pressed to an acceptable level using eptiﬁbatide. During this
period, she was transitioned to warfarin and commenced on clo-
pidogrel 75 mg daily. Subsequent hematologic testing demon-
strated a Jak2 mutation consistent with myeloproliferative
disorder. Her hydroxyurea was titrated, and on day 9 postoper-
atively, her platelet count was suppressed to 302  109/L and
eptiﬁbatide was discontinued. Four months postoperatively,
Fig. Diagnostic angiography of the left leg. A, Stenosis in mid superﬁcial femoral artery. B, Occluded distal superﬁcial
femoral artery with geniculate collaterals. C, Occluded tibial vessels. D, Reconstitution of distal posterior tibial artery
(arrowhead), which crosses the ankle joint.
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patent, and her ankle-brachial indices improved from unmeasur-
able to 0.72.
DISCUSSION
Peripheral vascular disease is a signiﬁcant health prob-
lem affecting between 13% and 14% of the elderly popula-
tion. It is predicted to affect >7 million adults older than
40 years by 2020 in the United States.1 Critical limb
ischemia is its most severe form, and untreated it is associ-
ated with a 1-year amputation rate of 44% and 1-year
mortality rate of 26%.2 Despite the improvements in endo-
vascular therapy for patients with critical limb ischemia, in
patients suitable for surgery, bypass remains an effective
and cost-efﬁcient treatment.3 Our patient presented emer-
gently with critical limb ischemia and impending limb loss.
Despite her thrombocytosis and possible myeloproliferative
disorder, the urgent limb-threatening nature of her
vascular disease required treatment before deﬁnitively
diagnosing and addressing her underlying hematologic
disorder. In the absence of thrombotic complications, the
standard treatment for thrombocytosis in this age group
is antiplatelet agents and observation alone. There was
signiﬁcant difﬁculty with recurrent on-table platelet-type
white thrombus. Such patients present a signiﬁcant clinical
challenge in balancing the need for emergency surgery
against the risk posed from undiagnosed comorbidities.
Early graft failure requiring reintervention is a signiﬁ-
cant postoperative complication for vascular surgeons.
Studies on data from the National Surgical QualityImprovement Program in the United States demonstrate
that early graft failure is associated with an increased mor-
tality rate and overall complications.4 The incidence at
30 days is between 4.5% and 6.3%. Risk factors associated
with early graft failure include female sex (odds ratio,
1.22-1.29) and thrombocytosis (odds ratio, 1.29-
1.49).4,5 Whereas long-term graft patency may be modiﬁed
by appropriate use of antiplatelet agents and anticoagula-
tion,6,7 the options for rescue therapy to salvage a failing
graft on table have not been studied.
Stimuli that generate platelet-rich thrombi converge on
a ﬁnal pathway involving platelet glycoprotein IIb/IIIa.
This receptormediates interplatelet bridging through ﬁbrin-
ogen. The intravenous glycoprotein receptor antagonists
(abciximab, tiroﬁban, and eptiﬁbatide) are inhibitors with
short half-lives that block this ﬁnal pathway of platelet
aggregation. They are used predominantly as adjuncts in
the management of myocardial infarction. Intracoronary
administration during angiography is described as rescue
therapy for thrombus formation.8 The use of these agents
outside the setting of coronary artery disease for acute
thrombosis has been described only for endovascular neuro-
interventional procedures. On-table arterial thrombosis is a
signiﬁcant complication of endovascular cerebral aneurysm
treatment. The use of direct intra-arterial eptiﬁbatide and
abciximab has been described in a number of reports with
acceptable bleeding rates and good therapeutic success at
resolving thrombosis.9-12 In addition, eptiﬁbatide has been
used for perioperative bridging as a short half-life alternative
to clopidogrel when the risk of bleeding is a concern.13,14
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concomitant leukocytosis and thrombocytosis, which was
subsequently diagnosed as a Jak2-positive myeloprolifera-
tive disorder. Myeloproliferative disorders arise from a
mutation in the Janus family tyrosine kinase Jak2. The Janus
family tyrosine kinase is used by the erythropoietin, throm-
bopoietin, and granulocyte colony-stimulating factor
receptors for ligand-stimulated signal transduction. When
the Jak2 mutation is activated, it leads to exaggerated clonal
hematopoiesis and results in the clinical myeloproliferative
syndromes. These are well-deﬁned risk factors for arterial
thrombosis.15 The recurrent acute thrombosis during
surgery that we encountered was classic platelet-rich white
thrombus. This occurred despite oral aspirin and satisfactory
perioperative anticoagulation with heparin. On the basis of
the previous history of use in neurointervention procedures
for salvage in cases of acute thrombosis and its rapid onset of
action, we treated our patient with eptiﬁbatide. The dose
chosen in our case was one third of that used in acute coro-
nary syndromes as our patient commenced treatment while
on the operating table. This ensured that despite thrombo-
cytosis, the functional platelet counts were suppressed. This
enabled successful completion of our surgical bypass until
the patient could be transitioned to additional oral clopidog-
rel and deﬁnitive treatment of her myeloproliferation with
hydroxyurea.
CONCLUSIONS
We present here a novel case of the use of intravenous
platelet inhibition with the glycoprotein IIb/IIIa antago-
nist eptiﬁbatide for on-table salvage of an infrainguinal
bypass graft. This represents an additional therapeutic
agent for the vascular surgeon in managing these complex
and challenging situations.REFERENCES
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